STAT

•

頻道 • 2 個節目

新聞

新聞

每兩星期更新
商業

商業

每星期更新

04/12/2025

380: A new top drug regulator and the future of psychedelics

On this week’s episode of "The Readout Loud": a look at an emerging class of psychedelic drugs that may treat depression, anxiety, and other psychiatric conditions without the hallucinogenic “trip.” Plus, a dash through the week’s biotech news. Our special guest this week is David Olson, director of the UC Davis Institute for Psychedelics and Neurotherapeutics and the co-founder of Delix Therapeutics, a startup that is developing a new class of neuropsychiatric medicines that are similar to psychedelics in that they can exert strong and rapid therapeutic benefits, but without the hallucinogenic effects.

04/12/2025

•

33 分鐘
18/03/2021

Episode 152: Alison Buttenheim on Europe's vaccine scare, Lilly's Alzheimer's data, & a PR plea

First we unpack the crisis of confidence facing AstraZeneca's Covid-19 vaccine in Europe with Alison Buttenheim, a University Pennsylvania professor who studies vaccine acceptance. Then, we explain the latest data on an Alzheimer's disease treatment from Eli Lilly and why it has polarized experts in the field. Finally, we make a modest proposal to the biotech industry: Give honesty a chance.

18/03/2021

•

30 分鐘
24/09/2020

Episode 130: A road map for Covid-19, the gold rush in health tech, & D.C.'s pandemic unrest

Is superspreading an Olympic event? Will Covid-19 forever change health tech? And what are the limits of Anthony Fauci's patience?

24/09/2020

•

26 分鐘
20/06/2019

Episode 68: A controversial desire drug, courtroom genealogy, & the quest for longer life

Is desire a matter of medicine? Can you convict on genealogy? And what do you get the alleged bride who has it all?

20/06/2019

•

27 分鐘
13/12/2018

Episode 40: Gilead’s new boss, the year that was, and the thing about DNA tests

Is Gilead Sciences entering a bold new era? What even happened in 2018? And how useful is a genetic credit score?

13/12/2018

•

23 分鐘
17/05/2018

Episode 11: Inside the Theranos collapse, Valeant's latest legal lumps, and a few biotech hot takes

What do you call a unicorn without a horn? Is your colleague wearing a wire? And is Jentadueto a drug name or a complicated espresso drink?

17/05/2018

•

23 分鐘
06/12/2018

Episode 39: Using the word 'cure,' an FDA loophole, & making biotech history

Can gene therapy cure sickle cell disease? Is an expensive drug better than a free one? And will biotech see its shadow in 2019?

06/12/2018

•

23 分鐘
11/11/2021

Episode 186: Rebecca Robbins on Moderna v. NIH, plus psilocybin as a medicine

Rebecca Robbins of the New York Times joins us to discuss the escalating tension between Moderna and the National Institutes of Health over just who invented a Covid-19 vaccine. Then, STAT's Olivia Goldhill calls in to explain Compass Pathways' promising results using psilocybin as a treatment for depression and the future of the nascent field of psychedelic medicines. We also discuss the latest news in the life sciences, including pills for Covid-19, the next FDA commissioner, and whether Pfizer CEO Albert Bourla listens to Joe Rogan.

11/11/2021

•

30 分鐘
23/01/2020

Episode 95: The latest on the China virus, Sarepta's ongoing FDA saga, and biotech at Davos

Are we dealing with a SARS redux? Has the FDA lost its teeth? And what do billionaires talk to each other about?

23/01/2020

•

22 分鐘
18/12/2020

Episode 141: Moderna's vaccine milestone, Warp Speed's hurdles, and biotech in 2021

It's the final episode of 2020. We dig into the second vaccine that's been recommended by a panel of FDA advisors, and look ahead to see what's in store for biotech in 2021.

18/12/2020

•

35 分鐘

Voices from the frontiers of health and medicine